Indonesia Strengthens Health Independence Through National Plasma Ecosystem
The Indonesian government is currently working hard to build a stronger national plasma ecosystem. This step is being taken as part of a grand strategy to improve domestic health resilience, particularly in the provision of Plasma Derived Medicinal Products (PDMP).
Plasma-derived products are vital medical components for treating various life-threatening health conditions. Some diseases that require this therapy include primary immunodeficiency, hemophilia, and various other immune system disorders. So far, reliance on imported products has been a major challenge for the national health system.
By building its own plasma ecosystem, Indonesia aims to reduce dependence on supplies from abroad. This development involves collaboration between various health agencies, including the Indonesian Red Cross and plasma processing facilities that meet international standards. This is expected to ensure the availability of vital medicines for patients in all corners of Indonesia.
In addition to increasing accessibility, this initiative is also expected to reduce treatment costs for the community. By producing plasma-derived products domestically, the prices of these medicines can become more affordable for patients who require long-term treatment.
Overall, strengthening the national plasma ecosystem is a strategic step for Indonesia to achieve independence in the pharmaceutical sector. This effort will not only strengthen the national health system but also provide better protection for people who require specialized medical care.